Founder and CEO
Róbert Wessman is the visionary behind Alvotech, known for his passion for improving patient lives and the global healthcare ecosystem, his unwavering focus and his ability to successfully combine operational efficiency with growth through strategic acquisitions. He recognized the potential early on for locating a biotechnology company in Iceland and founded Alvotech in 2013, further contributing to the pharmaceutical industry growth there.
Prior to founding Alvotech, Róbert Wessman transformed Actavis, originally a small domestic pharmaceutical company, into the fourth largest generics company in the world within 7 years as CEO. He also founded Alvogen in 2009 as a US-based CMO prior to growing it into a top global generics company over the course of 6 years. In total over his more than 20-year career in the pharmaceutical industry, he has led over 50 strategic acquisitions and partnerships and established operations in over 60 countries around the world.
His leadership and achievements have made him the subject of three Harvard Business School Case Studies, “Róbert Wessman and the Actavis Winning Formula” (2008), “Alvogen” (2015) and “Alvogen: Scaling Entrepreneurship” (2018). Róbert is a business graduate and former lecturer at the University of Iceland.